This site is still under development. Information, features, and some organizational
aspects of the data still need further work and will change as we continue building.

Targretin

Hover over a term you want explained. If you need more details, then click on the term and a new tab will open with a full details page.

What Targretin Means in Everyday Medical Language

Targretin is a medicine also known as bexarotene or LGD1069. It is mainly used to treat skin problems caused by cutaneous T-cell lymphoma, a rare cancer that affects certain white blood cells called T cells in the skin. Bexarotene belongs to a group of drugs called retinoids, which are related to vitamin A. It works by activating proteins inside cells called retinoid X receptors. This action may help stop cancer cells from growing and may lead to their death.

Why Targretin Can Matter in Cancer Care

Cutaneous T-cell lymphoma can cause persistent and uncomfortable skin problems that affect quality of life. When standard treatments like chemotherapy, radiation, or other therapies do not improve these symptoms, Targretin offers another option that may help control the disease. It is important to understand that Targretin is not a cure but a treatment that may help manage symptoms and slow disease progression. Doctors usually consider Targretin when other treatments have not worked well or are not suitable.

What Patients Might See or Hear About Targretin

Patients may hear the name Targretin, bexarotene, or LGD1069 during visits with their doctor or when reviewing treatment plans. These different names all refer to the same medicine. You might also see these names in drug information sheets, clinical trial listings, or cancer care resources. Hearing about Targretin does not mean the cancer is advanced or untreatable; rather, it is one of several treatment options that might be discussed to help manage skin symptoms from lymphoma.

Where Targretin Might Appear in Care and Information

Targretin or bexarotene may be mentioned in medical reports, treatment plans, or visit notes when discussing options for managing cutaneous T-cell lymphoma. It can also appear on clinical trial pages if patients are considering research studies. Drug information pages often provide details about how the medicine works, possible side effects, and monitoring needs. Knowing the different names can help patients recognize information about the drug in various settings.

Common Questions Patients Can Ask Their Care Team

Patients and caregivers may want to ask: How does Targretin work? What side effects should I watch for? How will we know if it is helping? Are there other treatments I should consider? Is Targretin part of a clinical trial I might join? These questions can help patients understand how this medicine fits into their overall care plan.

How to Read Targretin in Context

It is important to look at the full context when Targretin is mentioned—such as the type of cancer being treated, the stage of disease, and other treatments planned—rather than focusing on the drug name alone. This helps avoid misunderstanding its role or effectiveness. Targretin is approved specifically for skin problems caused by cutaneous T-cell lymphoma that have not responded to other treatments. It is not used for all cancers and is not a cure.

Safety and Next Steps

This information is meant to educate and support patients and caregivers. It does not replace medical advice or decide what is safe or appropriate for any individual. If you see Targretin mentioned in your medical records or treatment plan, the safest next step is to ask your healthcare team what it means for your specific situation and how it fits into your care. They can provide guidance tailored to your needs and help you understand the benefits and risks of this treatment option.

Sources

Public source information used for this glossary entry includes: